Identifying Who May Be at Risk for Ozempic-Related Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Risk Communication

If you or a loved one has been taking Ozempic and noticed persistent nausea, bloating, or abdominal pain after meals, these could be early signs of gastroparesis—a condition where the stomach empties too slowly. The growing body of clinical observations around this medication's gastrointestinal effects has prompted a closer look at which patients may be most vulnerable. This page provides a clear, evidence-based overview of the risk factors and warning signals associated with Ozempic and gastroparesis.

The Medical Link Between Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which can contribute to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has been reported in association with Ozempic use. Gastroparesis presents clinically with nausea, vomiting, early satiety, bloating, and abdominal pain, and diagnosis typically involves gastric emptying scintigraphy or breath testing. The mechanistic link between Ozempic and gastroparesis is rooted in the drug's effect on GLP-1 receptors, which inhibit gastric motility and can lead to prolonged gastric retention, potentially exacerbating or unmasking gastroparesis in susceptible individuals. Clinical trial data from the Ozempic prescribing information document a significantly higher incidence of gastrointestinal adverse reactions in treated patients compared to placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea reports occurred during dose escalation, and discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients (3.1% for 0.5 mg, 3.8% for 1 mg) versus placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% and 34.0% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in at least 5% of Ozempic-treated patients included nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% and 9.2%), diarrhea (8.5% and 8.8%), abdominal pain (7.3% and 5.7%), and constipation (5.0% and 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these data do not explicitly diagnose gastroparesis, the high rates of nausea, vomiting, and abdominal pain are consistent with gastroparesis symptomatology.

Labeling Gaps and Legal Implications for Illinois Patients

The adequacy of warnings regarding Ozempic and gastroparesis is a key risk anchor. The prescribing information includes a section on hypersensitivity reactions, such as anaphylaxis and angioedema, but does not specifically list gastroparesis as a warning or precaution (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label does note that gastrointestinal adverse reactions are common and often occur during dose escalation, but it does not explicitly warn of the potential for gastroparesis as a distinct adverse effect. This gap in labeling may affect the ability of patients and healthcare providers to recognize and manage the condition early, potentially leading to delayed diagnosis and prolonged harm. For affected patients in Illinois, settlement-related considerations depend on the statute of limitations for product liability claims. In Illinois, the statute of limitations for personal injury claims, including those related to defective drugs, is generally two years from the date the injury was discovered or should have been discovered. For Ozempic-associated gastroparesis, the timeline between exposure and documented harm is critical. Patients may develop symptoms weeks to months after starting Ozempic, and the condition can persist or worsen even after discontinuation. The discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Ozempic caused their gastroparesis. Given that gastrointestinal symptoms are common with Ozempic and often attributed to the drug's known effects, patients may not immediately recognize gastroparesis as a distinct harm. This could extend the filing window, but it also underscores the importance of timely medical evaluation and documentation. In summary, Ozempic use is associated with a high incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The prescribing information does not specifically warn about gastroparesis, which may impact patient awareness and legal claims. Illinois patients should be aware of the two-year statute of limitations from the date of discovery of harm, and the timeline between Ozempic exposure and gastroparesis diagnosis is a key factor in determining eligibility for settlement. Legal consultation is recommended to assess individual circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for an Ozempic gastroparesis claim in Illinois?

In Illinois, the statute of limitations for personal injury claims, including product liability claims related to Ozempic, is generally two years from the date the injury was discovered or should have been discovered. This means that if you developed gastroparesis after taking Ozempic, you typically have two years from the time you knew or reasonably should have known that Ozempic caused your condition to file a lawsuit. Because gastrointestinal symptoms are common with Ozempic, the discovery date may be later than the onset of symptoms. It is crucial to consult with an attorney to determine your specific deadline.

Does the Ozempic label warn about gastroparesis?

The Ozempic prescribing information does not specifically list gastroparesis as a warning or precaution. While it notes that gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain are common, it does not explicitly warn of the potential for gastroparesis as a distinct adverse effect. This labeling gap may affect patient awareness and legal claims. For more details, refer to the prescribing information at (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.